Leap Therapeutics stock jumps 47% on positive DKN-01 + tislelizumab data in gastroesophageal cancer

0
medium_image_1248262649.jpg

Leap Therapeutics stock jumps 47% on positive DKN-01 + tislelizumab data in gastroesophageal cancer

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *